Advisory Research Inc. continued to hold its stake in shares of Balchem Corporation (NASDAQ:BCPC) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,421 shares of the basic materials company’s stock at the end of the 2nd quarter. Advisory Research Inc. owned 0.09% of Balchem Corporation worth $2,342,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of BCPC. Tributary Capital Management LLC grew its stake in Balchem Corporation by 11.9% in the second quarter. Tributary Capital Management LLC now owns 187,925 shares of the basic materials company’s stock worth $14,604,000 after purchasing an additional 19,973 shares during the period. Congress Asset Management Co. MA grew its stake in Balchem Corporation by 9.6% in the second quarter. Congress Asset Management Co. MA now owns 19,858 shares of the basic materials company’s stock worth $1,543,000 after purchasing an additional 1,738 shares during the period. Municipal Employees Retirement System of Michigan grew its stake in Balchem Corporation by 4.0% in the second quarter. Municipal Employees Retirement System of Michigan now owns 7,500 shares of the basic materials company’s stock worth $583,000 after purchasing an additional 290 shares during the period. American Capital Management Inc. purchased a new stake in Balchem Corporation in the second quarter worth $218,000. Finally, Great West Life Assurance Co. Can grew its stake in Balchem Corporation by 3.8% in the second quarter. Great West Life Assurance Co. Can now owns 45,991 shares of the basic materials company’s stock worth $3,570,000 after purchasing an additional 1,678 shares during the period. 84.22% of the stock is currently owned by institutional investors.
Shares of Balchem Corporation (NASDAQ:BCPC) traded up 0.09% during midday trading on Wednesday, reaching $81.80. The company had a trading volume of 757 shares. Balchem Corporation has a 1-year low of $67.71 and a 1-year high of $89.50. The stock has a market capitalization of $2.61 billion, a price-to-earnings ratio of 42.38 and a beta of 1.12. The firm’s 50 day moving average price is $77.91 and its 200-day moving average price is $78.59.
Balchem Corporation (NASDAQ:BCPC) last released its quarterly earnings data on Friday, August 4th. The basic materials company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.63 by $0.01. The company had revenue of $147.08 million for the quarter. Balchem Corporation had a return on equity of 14.99% and a net margin of 10.99%. Equities research analysts expect that Balchem Corporation will post $2.47 EPS for the current fiscal year.
WARNING: This story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://sportsperspectives.com/2017/10/11/advisory-research-inc-has-2342000-stake-in-balchem-corporation-bcpc.html.
Separately, BidaskClub cut Balchem Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, June 21st.
About Balchem Corporation
Balchem Corporation is engaged in the development, manufacture and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization and industrial markets. The Company operates in four segments: Human Nutrition & Health, Animal Nutrition & Health, Specialty Products and Industrial Products.
Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Corporation (NASDAQ:BCPC).
Receive News & Ratings for Balchem Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem Corporation and related companies with MarketBeat.com's FREE daily email newsletter.